Global Radiodermatitis Market to Reach a Value of More Than USD 570 Million by 2027, Aided by the Increased Incidences of Cancer

The rapidly rising cases of cancer across the globe and the increased use of radiotherapy for treatment are predicted to propel the market growth of radiodermatitis. Radiodermatitis is a side effect of radiation therapy, which is believed to occur in 85 percent of cancer patients who are treated with radiation, according to the National Institute of Health. In this regard, cancer patients are increasingly looking for effective palliative care alternatives to help them cope with the severe consequences of radiation. The growing number of clinical trials being conducted to assess the efficacy of a variety of radiodermatitis treatments is expected to boost the product pipeline. Further, the rising demand for eradicating radiation therapy-related side effects is expected to provide the radiodermatitis sector with promising growth potential during the forecast period. Due to the rising prevalence of cancer in the United States, North America is expected to be a substantial market for radiodermatitis in the coming years. Moreover, the growing number of public and private healthcare organisations actively raising awareness about radiodermatitis management and treatment is expected to positively impact the industry.

The factors such as the escalating number of product launches concerning radiodermatitis treatment, fuelled by the rising consumer demand are expected to boost the overall market growth in the forecast years. For instance, in July 2017, Stratpharma AG, a company that specialises in manufacturing topical products, launched StrataXRT, a topical wound dressing for radiation dermatitis. StrataXRT is a flexible wound dressing that promotes a moist wound healing environment for quicker healing and re-epithelialisation following radiation therapy. Meanwhile, in November 2021, Enveric Biosciences (NASDAQ: ENVB), a leading biotechnology firm, announced that its EV102 has demonstrated positive preclinical results by helping in significantly reducing the dermatitis severity and skin redness. The EV102 is the company’s topical prescription treatment for radiodermatitis based on cannabidiol. Such developments are expected to support the growth of the radiodermatitis industry in the forecast period.

Market Analysis by Products, Distribution Channels, and Regions:

• The market, based on product, can be segregated into topical, oral, and dressings. Among these, the topical segment is divided, on the basis of type, into corticosteroids, hydrophilic creams, and antibiotics, among others. Meanwhile, the oral segment is bifurcated into corticosteroids, and oral analgesics and antibiotics. Further, the dressings segment can be divided, by type, into hydrogel and hydrocolloid dressing, no sting barrier film, honey impregnated gauze, and silicone coated, among others.
• On the basis of distribution channel, the market can be classified into hospital pharmacy, retail pharmacy, and online pharmacies, among others.
• The regional markets for radiodermatitis include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• The rising public and private investments in the development of advanced cancer treatments are projected to propel the global market for radiodermatitis in the forecast period.
• The need for radiodermatitis is also expected to be fuelled by the rising geriatric population.
• The growing demand for radiation therapy owing to the rising incidences of various types of cancers is expected to be a major driving force for the industry. 
• The increasing research and development activities in the area of life sciences are expected to significantly contribute to the growth of the market.

Key Offerings of the report:

• The EMR report gives an overview of the global market for radiodermatitis for the periods (2017-2021) and (2022-2027).    
• The report also offers the historical (2017-2021) and forecasted (2022-2027) markets for the products, distribution channels, and major regions of radiodermatitis.  
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global radiodermatitis market are BMG Pharma S.p.A., and Stratpharma AG, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.